Marcy-l’Étoile (France), January 22nd, 2026 – bioMérieux, a world leader in the field of in vitro diagnostics, announces the acquisition of Accellix, a US company specializing in rapid, automated flow cytometry solutions for cell and gene therapy quality control. With this strategic transaction, bioMérieux strengthens its Pharmaceutical Quality Control activity and invests in innovative solutions […]
bioMérieux Acquires Accellix to Elevate Pharmaceutical Quality Control and Accelerate Advanced Therapies
January 22, 2026 – 12:00 am
Accellix, Inc. and Streck collaborate to advance cell therapy with quality control
September 24, 2025 – 4:45 am
SAN JOSE, CA and LA VISTA, NE — Accellix™, a pioneer in automated flow cytometry, and Streck, a recognized leader in quality control materials for flow cytometry, hematology and molecular diagnostics, have announced a strategic collaboration with the addition of the Accellix Automated Cell Phenotyping Platform to Streck’s CD-Chex Plus® (RUO) control. The Accellix platform […]
Accellix Appoints Dr. Félix A. Montero-Julian as Vice President of Scientific Affairs
July 6, 2025 – 11:00 pm
SAN JOSE, California – Accellix, a global leader in rapid point of need cytometry solutions, is pleased to announce the appointment of Félix A. Montero-Julian, PhD as Vice President of Scientific Affairs. Dr. Montero-Julian brings more than 30 years of international experience in scientific affairs, analytical development, and regulatory science to support Accellix’s strategic vision […]
Accellix Platform Chosen by the American Red Cross for Rapid and Accurate Allogeneic Source Material Characterization for Cell Therapy Development
December 3, 2024 – 5:00 am
SAN JOSE, California & WASHINGTON — The American Red Cross Cell and Gene Therapy Solutions (CGTS) division, a leading single-source provider for allogeneic cell therapy source material, has selected Accellix, Inc., the developer of the point-of-need testing automated flow cytometry platform, to provide Accellix instruments and assays at its CGTS collection sites to improve characterization […]
Accellix Appoints Greg Hamilton as Chief Executive Officer as Company Accelerates Growth in Cell Therapy and Blood Bank Markets
September 23, 2024 – 10:00 am
SAN JOSE, Calif. & JERUSALEM — Accellix, Inc., the leading sample to answer flow cytometry GMP platform company, is pleased to announce the appointment of Greg Hamilton as Chief Executive Officer and member of the Board effective September 23, 2024. He brings over 25 years of management experience in molecular diagnostics, life science tools, manufacturing […]
Accellix Raises $10 Million From BroadOak Capital Partners
December 13, 2021 – 10:38 am
Accellix will use the investment to expand its commercial resources and infrastructure in support of its cell therapy customers SAN JOSE, Calif. & BETHESDA, Md. — Accellix Inc., which provides quick and accurate flow cytometry results in a compact and easy-to-use platform designed for use by cell therapy companies on the manufacturing floor and at […]
Accellix Expands its Leadership Team
May 11, 2021 – 11:09 am
SAN JOSE, Calif. & JERUSALEM — Accellix Inc. is pleased to announce that Terrance Gin is joining its leadership team as Vice President Global Operations effective immediately. Terrance brings over 30 years of management experience in IVD manufacturing, process and product development, clinical laboratory operations, quality assurance, capital improvement, facility, and EH&S. He was VP […]
bioMérieux signs agreement with Accellix, for the Asia Pacific region
May 5, 2021 – 11:07 am
bioMérieux strengthens its Quality Control Offering in Advanced Therapy Medicinal Products (ATMP) Marcy-l’Étoile, France and San Jose, California — bioMérieux is designated as the exclusive distributor of Accellix products in China, Japan, Australia and South Korea. Under the agreement signed on February 18th, 2021, bioMérieux will perform the full range of sales, supply and service […]
Accellix, the Cell Therapy QC company raises $9.5 million Series D round
June 11, 2020 – 11:02 am
SAN JOSE, Calif. & JERUSALEM — Today Accellix, the Cell Therapy QC company, announced a Series D financing round of $9.5 million led by bioMérieux, a world leader in the field of in vitro diagnostics for over 55 years. All existing major investors participated in this raise and have also agreed to convert their pre-existing […]
Announcing the Next Generation Accellix Instrument and Consumable
April 29, 2020 – 11:04 am
Further Simplifying and Automating the QC Workflow in Cell Therapy Manufacturing SAN JOSE, Calif. & JERUSALEM — Accellix, Inc. is launching its Next Generation Integrated Accellix Instrument and Consumables to further automate, simplify and improve reproducibility during the intricate process of QC for cell therapy manufacturing. Accellix entered the cell therapy market in 2017, automating […]
Nir Nimrodi Appointed as Chairman and Chief Executive Officer
January 15, 2020 – 11:00 am
Nimrodi Will Lead the Company’s Accelerated Growth as It Launches Custom and Standardized Panel Assays to Be Used by Its Expanding Installed Base. SAN JOSE, Calif. & JERUSALEM — Accellix, Inc. is pleased to announce the appointment of Nir Nimrodi as Chairman and Chief Executive Officer effective immediately. Mr. Nimrodi has served as the Executive […]
Charles Piazza Appointed to Accellix Board of Directors
August 14, 2019 – 10:59 am
SAN JOSE, Calif. — Accellix Inc. announces the appointment of a new Board Member, Mr. Charles Piazza. Charles (Chuck) Piazza, Accellix’s newest board member, has over 35 years of global experience within the life science industry serving the pharmaceutical, biotechnology and medical research sectors. His recent positions included Vice President and General Manager for the […]
Accellix Expands Leadership Team and Announces Name Change
July 25, 2019 – 10:56 am
SAN JOSE, Calif. & JERUSALEM — LeukoDx, Inc. (“the Company”), is pleased to announce the official name change to Accellix, Inc. (“Accellix”) effective immediately. “The cell therapy market needs a new testing paradigm that can deliver rapid results, and one that can scale to meet the expanding adoption of therapy regimens. The
